Notas de prensa
Siempre tenemos algo en marcha, ya sea un nuevo producto que permite una innovadora investigación, una alianza estratégica con un cliente o una alianza solidaria que consolida nuestra misión. A continuación encontrará nuestras notas de prensa más recientes, así como un filtro para agilizar aún más su búsqueda.
Contacto
Sólo para consultas de periodista, comuníquese con:
Rachel Bloom-Baglin
Teléfono: +1 978 436 1725
Sep 10, 2024
MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate ManufacturingMilliporeSigma launched the first single-use reactor specifically designed to manufacture antibody drug conjugates (ADCs).
Sep 03, 2024
MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media ManufacturingMilliporeSigma today announced that the company’s Life Science business achieved EXCiPACT cGMP certification for PAMs at its major global CCM production sites.
Aug 01, 2024
MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing OfferingMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced that the company’s Life Science business has closed the transaction to acquire Mirus Bio.
Jul 24, 2024
MilliporeSigma Announces Signing of MoU with Gene Therapy Research Institution to Accelerate Viral Vector-based Gene Therapy for Parkinson’s DiseaseMilliporeSigma announced that its Life Science business sector has signed a non-binding MoU with Gene Therapy Research Institution Co., Ltd. (GTRI).
Jul 03, 2024
MilliporeSigma Announces Non-Binding MoU with Afrigen Biologics for Development of mRNA Vaccine Technology PlatformMilliporeSigma announced that the company’s Life Science business entered into a non-binding Memorandum of Understanding (MoU) with Afrigen Biologics to support the development of an mRNA vaccine technology platform.
Jun 18, 2024
MilliporeSigma and The Michael J. Fox Foundation Offer Service to Advance Parkinson’s researchSMC® immunoassay technology from MilliporeSigma provides new understanding of cell dysfunction to slow disease progression
Jun 11, 2024
MilliporeSigma Announces € 62 Million Investment in New Quality Control Facility in Darmstadt, GermanyFacility to provide production-related quality control services for Life Science business and brings together 135 employees and various functions into one ~10,000 m2 building.
Jun 06, 2024
MilliporeSigma Announces Completion of € 180 Million Schnelldorf Distribution Center ExpansionExpands facility by 25,000 square meters, nearly doubling size, adds new down filling capabilities and distribution space for Life Science customers, employs more than 470 people, including engineers, manufacturing, and distribution experts
Jun 04, 2024
MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech GrantMilliporeSigma announced today that Siren Biotechnology has been selected as the North American winner of its 13th Advance Biotech Grant Program.
May 29, 2024
MilliporeSigma Signs MoU with KAIST to Advance Scientific CollaborationMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with KAIST.
May 28, 2024
MilliporeSigma Launches First Software for Complete Data Traceability in Microbial Quality ControlMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched its M-Trace® Software & Mobile App, a comprehensive data tracking solution to digitize sterility testing.
May 22, 2024
MilliporeSigma Signs Definitive Agreement to Acquire Mirus Bio, Furthering Ambition to Be a Leading Supplier for Viral Vector ManufacturingMilliporeSigma today announced the signing of a definitive agreement to acquire Mirus Bio for US$ 600 million.
Apr 17, 2024
MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube TourMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany.
Apr 16, 2024
MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety TestingMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.
Mar 20, 2024
MilliporeSigma Invests More than € 300 Million in New Life Science Production Site in KoreaMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, invests more than €300 million into a new Bioprocessing Production Center in Daejeon, South Korea.
Jan 24, 2024
MilliporeSigma Announces a Non-Binding MoU with Mycenax Biotech to Drive Innovation in Bioprocessing TechnologyMilliporeSigma announced that the Life Science business sector entered into a non-binding MoU with Mycenax Biotech to explore cooperation to bring innovative and high-capacity bioprocessing solutions to Taiwan and other international markets.
Dec 05, 2023
MilliporeSigma Launches First Ever AI Solution to Integrate Drug Discovery and SynthesisCombines generative AI, machine learning and computer-aided drug-design to increase the success rate of new drugs and therapies
Nov 21, 2023
MilliporeSigma Expands Newest Biologics Testing Center in ShanghaiFurther develops its biosafety testing laboratories to meet local demand; new labs complete 2nd phase of company’s € 29 million Biologics Testing Center opened in 2022.
Nov 14, 2023
MilliporeSigma Launches ChemisTwin™, First Ever Digital Reference Materials Platform for Analytical TestingAccelerates digitalization in labs and manufacturing by offering traceable digital records of physical reference materials.
Sep 26, 2023
MilliporeSigma to Become First Provider to Offer Fully Integrated mRNA ServicesMilliporeSigma is the first CTDMO to offer integrated services for all critical stages of mRNA development, manufacturing, and commercialization, including products and testing.
Jul 12, 2023
MilliporeSigma Invests $25 Million to Expand Cell Culture Media Production in KansasLenexa, Kansas, facility becomes company’s largest dry powder cell culture media facility and Center of Excellence
Jun 06, 2023
MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech GrantMilliporeSigma announced that Proteologix US Inc. (“Proteologix”) has been selected as the North American winner of its 12th Advance Biotech Grant program.
May 31, 2023
Life Science Business of Merck KGaA, Darmstadt, Germany Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine ManufacturersAccording to a recent study sponsored by the Life Science business of Merck KGaA, Darmstadt, Germany, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.
May 31, 2023
MilliporeSigma Increases Global Commitment to Biosafety Testing With € 35 Million Investment in ScotlandResponds to global demand for biosafety testing for drug development and commercialization. Expansion creates nearly 500 new jobs in Glasgow and Stirling. Company’s investment to boost global testing capacity now tops € 350 million since mid-2022.
May 02, 2023
MilliporeSigma Signs MoU for New BioProcessing CenterMilliporeSigma partners with MOTIE and Daejeon City for a new Asia-Pacific BioProcessing Center to advance life science.
Apr 26, 2023
MilliporeSigma Kicks Off 2023 Curiosity Cube Mobile Lab TourOver 250 events expected to reach more than 45,000 future scientists on two continents. Hands-on experiments to focus on the impact of contamination on the planet and everyday life.
Apr 24, 2023
MilliporeSigma Launches Ultimus® Film to Offer Superior Strength and Leak Resistance in Single-use AssembliesMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the launch of its Ultimus® Single-Use Process Container Film.
Mar 27, 2023
MilliporeSigma Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry EducationPartnership to support Beyond Benign’s online learning platform and higher education program
Dec 07, 2022
MoU: MilliporeSigma & Synplogen for Gene TherapyNon-binding MoU signed between MilliporeSigma and Synplogen for collaborative initiatives.
Dec 06, 2022
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems AcquisitionMilliporeSigma a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems.
Nov 16, 2022
MilliporeSigma Invests $ 286 Million in U.S. Drug Safety Testing CapacityMilliporeSigma today announced that its Life Science business sector is investing more than $ 286 million in its biosafety testing capacity at the company’s site in Rockville, Maryland.
Nov 07, 2022
MilliporeSigma Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in ChinaMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration with Biotheus.
Oct 04, 2022
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO ServicesThe Life Science business of Merck KGaA, Darmstadt, Germany, has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France.
Sep 21, 2022
MilliporeSigma Announces Opening of New € 29 Million Biologics Testing Center in ShanghaiMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.
Sep 08, 2022
MilliporeSigma Announces Investment of More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, FranceMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced that the Life Science business strengthened its manufacturing capabilities for single-use assemblies.
Aug 08, 2022
MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production PlatformMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform.
Jul 19, 2022
New Solar Panels at MilliporeSigma’s Wisconsin Site Add Renewable Energy to Power Grid7,000 solar panels produce energy to power 700 homes, Part of We Energies’ “Solar Now” program, bringing more renewable energy to Wisconsin, Reinforces company’s long-term commitment to renewable energy.
Jul 18, 2022
MilliporeSigma Breaks Ground on Company’s First Lateral Flow Membrane Production Facility in the United StatesNew facility to manufacture the company’s Hi-Flow™ Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19
Jun 29, 2022
MilliporeSigma Signs MoU with Lotte Biologics for Biologics ManufacturingMilliporeSigma signed a non-binding Memorandum of Understanding (MoU) with the new biologics business of Lotte Group, outlining a planned collaboration to establish Lotte’s biologics manufacturing capabilities in the USA.
Jun 21, 2022
MilliporeSigma Opens €59M CDMO Facility for Cancer TherapiesMilliporeSigma doubles high-potent active pharmaceutical ingredients (HPAPI) production capacity at Verona, Wisconsin facility.
Jun 14, 2022
MilliporeSigma Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream ProcessingThe Life Science business of Merck KGaA, Darmstadt, Germany, collaborates with Agilent Technologies to advance Process Analytical Technologies (PAT).
May 23, 2022
MilliporeSigma Announces the Investment of More Than €440 Million and Expansion of Membrane and Filtration Manufacturing in IrelandThe investment, which is the largest in a single site ever for the Life Science business sector, significantly increases membrane manufacturing capacities and enables the construction of a new filtration manufacturing facility.
May 18, 2022
MilliporeSigma Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile LabMilliporeSigma today announced that the Life Science business further enhanced its commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of its 2022 Curiosity Cube® mobile science lab in Europe and North America.
Apr 28, 2022
MilliporeSigma Announces Investment of Approximately € 100 Million to Accelerate Single-Use Manufacturing in ChinaMilliporeSigma’s First Asia Pacific Mobius® Single-Use Manufacturing Center in Wuxi, China
Apr 21, 2022
MilliporeSigma Transforms Media Preparation and Dispensing with New ReadyStream® SystemReadyStream® system offers automated media preparation to conveniently provide a large volume of preheated media, eliminates five time-consuming steps.
Apr 14, 2022
MilliporeSigma’s ZooMAb® Antibodies Earns First-Ever ACT Label from My Green LabZooMAb® antibodies first-ever antibody to be recognized for low-environmental impact by My Green Lab
Apr 05, 2022
MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing CapabilitiesMilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies.
Feb 22, 2022
MilliporeSigma Renewable Energy InitiativeMilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Feb 15, 2022
MilliporeSigma and Waters to Collaborate on Extractables and Leachables Reference LibraryMilliporeSigma's Life Science business sector has entered into a collaboration with Waters Corporation to build and expand an Extractables and Leachables (E&L) Reference Library to include ion mobility measurements
Feb 07, 2022
MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future GrowthMilliporeSigma today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.
Jan 26, 2022
MilliporeSigma Announces MoU with ID Pharma to Accelerate Development and Manufacturing of Gene TherapyMilliporeSigma, a leading science and technology company, today announced that the Life Science business sector signed a non-binding Memorandum of Understanding (MoU) with ID Pharma, the advanced medical business within I’rom Group, outlining its planned support of the development and manufacturing of leading-edge gene therapy.
Mar 03, 2020
MilliporeSigma’s New LANEXO® System to Improve Scientists’ Productivity in the LabMilliporeSigma today launched its LANEXO® Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.
Dec 10, 2018
MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent ModelsMilliporeSigma, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?